9.21  0.05 (0.55%)		04-26 16:00
Open: 9.15 High: 9.3 Volume: 153,477		Pre. Close: 9.16 Low: 9.04 Market Cap: 250(M)

Short term
Mid term
Targets	6-month :	12.21	1-year :	13.39
Resists	First :	10.46	Second :	11.47
Pivot price	9.93
Supports	First :	8.83	Second :	7.34
MAs	MA(5) :	9.21	MA(20) :	10.15
	MA(100) :	10.08	MA(250) :	8.83
MACD	MACD :	-0.4	Signal :	-0.2
%K %D	K(14,3) :	12	D(3) :	9.9
RSI	RSI(14): 32.5
52-week	High :	11.92	Low :	6.3

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ FENC ] has closed above bottom band by 23.3%. Bollinger Bands are 64.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	9.31 - 9.34	9.34 - 9.39
Low:	8.94 - 8.98	8.98 - 9.03
Close:	9.14 - 9.2	9.2 - 9.27

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Mon, 22 Apr 2024
Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in Stock - MarketBeat

Mon, 22 Apr 2024
Fennec Pharmaceuticals COO sells over $400k in company stock - Investing.com South Africa

Thu, 18 Apr 2024
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC) - Simply Wall St

Wed, 17 Apr 2024
Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells 22,222 Shares of Stock - MarketBeat

Tue, 16 Apr 2024
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Update - MarketBeat

Tue, 09 Apr 2024
Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136% - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	27 (M)
Shares Float	15 (M)
Held by Insiders	14.6 (%)
Held by Institutions	55.2 (%)
Shares Short	1,810 (K)
Shares Short P.Month	1,710 (K)

EPS	-0.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.44
Profit Margin	-75.5 %
Operating Margin	-18.7 %
Return on Assets (ttm)	-29.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	534.2 %
Gross Profit (p.s.)	0
Sales Per Share	0.78
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-17 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-15.35
PEG Ratio	0
Price to Book value	-21.42
Price to Sales	11.74
Price to Cash Flow	-14.57

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.